Following an inter partes review requested by 10x Genomics, the Patent Trial and Appeal Board invalidated a number of claims in a RainDance patent.
The two new single-cell RNA-sequencing methods aim to overcome some of the limitations of single-cell transcriptomics.
Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.
The companies will merge 10x's Chromium system and PerkinElmer's automation solutions into a combined NGS solution for researchers.
The approach, which uses 10x Genomics technology for haplotyping, requires neither mutation-specific assays nor DNA from affected family members.
By analyzing the transcriptomes of more than 4,000 individual cells, researchers identified stem cell-like cellular subpopulations in six oligodendroglioma tumors.
The researchers have generated the most contiguous de novo assembly of a human genome to date and plan to use it as a reference for population sequencing projects.
The deal comes on the heels of four other distribution agreements the firm has signed in the Asia-Pacific region for its Chromium molecular barcoding system and products.
The genomics company said the new agreements cover South Korea, Australia, New Zealand, Southeast Asia, and China.
The hybrid approach expands on one described last year by Mount Sinai researchers, and relies on short-read sequencing, linked-read sequencing, and genome mapping.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.